

## Presentation

Breast cancer mortality is declining in most countries; a detailed knowledge of the mechanisms of cancer progression, phenotypic and genotypic characterization of the disease, screening programs, advanced imaging, local therapies and molecularly targeted drugs have all been fundamental to achieve this success. Nowadays, breast cancer represents the front runner in the path to comparative effectiveness, where new therapeutic interventions are implemented on the basis of "average" benefit, to personalized cancer medicine, where the right treatment is provided to the right patient at the right moment. An updated, multifaceted approach to our patients is now becoming more and more demanding and with these goals in mind, the Programme of this international Conference includes lectures on molecular characterization, updated management of early and advanced disease, strategies to overcome resistance to available therapies, innovative therapies, and multimodal treatments for advanced disease.

Clinical case discussions and debates are planned to allow a continuous and fruitful exchange of experiences and opinions between speakers and participants. This 10<sup>th</sup> Breast Cancer Conference includes a highly qualified international faculty, but will maintain its characteristics of a friendly forum where international opinion leaders and attendees will exchange experiences and share the most exiting advances.

In order to reward scientific excellence and to foster international cooperation, the International Scientific Committee of the 10<sup>th</sup> AIBCC will award the 4<sup>th</sup> International Prize for Breast Cancer Research to a scientist who has published a breakthrough paper in the previous year and the Monica Boscolo Research Grant to an Italian scientist for a research project to be conducted in cooperation with a foreign institution.

We welcome medical oncologists, pathologists, breast surgeons, radiation oncologists and basic scientists to listen to breast cancer leaders and to exchange experiences in a friendly atmosphere.

## Addressed to

The Meeting is addressed to physicians specialized in: oncology, radiodiagnostics, radiotherapy, clinical pathology, general surgery, gynaecology and obstetrics, biologists and nurses.

# **Programme**

## Thursday, November 6th

8.00 Registration	n
-------------------	---

### 8.45 Introduction to the Conference

Pier Franco Conte, Gabriel N. Hortobagyi

#### **SESSION I - PATHOLOGY**

Chairmen: Alberto Amadori, Massimo Rugge

## 9.00 Standardization of breast cancer diagnosis: pathology

Anna Sapino

## 9.30 Standardization of breast cancer diagnosis: genomics

Giampaolo Bianchini

#### **SESSION II - LOCOREGIONAL THERAPIES**

Chairmen: Nicola Balestrieri, Graziano Meneghini

## 10.00 Evolving loco-regional management

- Post-mastectomy radiotherapy: a new standard? Philip Poortmans
- Management of the axilla: an update after recent trials Carlos A. Garcia-Etienne
- Hypofractionated breast irradiation Philip Poortmans

#### 11.00 Discussion

#### 11.20 Coffee break

#### **SESSION III - IMAGING**

Chairmen: Gabriel N. Hortobagyi, Luigi Pescarini

## 11.40 Role of MRI in breast cancer diagnosis

Clinical cases will be presented to discuss the following items:

- Is MRI the standard screening procedure in young women? Enrica Baldan
- Is MRI the gold standard to assess the response to neoadjuvant therapy? – Ilaria Polico
- Is MRI appropriate to plan the type of surgery? Alessandro Coran

The audience will be asked to vote. After the vote, two senior speakers will debate items in favor or contra. The audience will be asked to vote again after the debate.

Pro: Pietro Panizza Contra: Petra Steyerova

Conclusive remarks of the Chairmen

13.15	Lunch
13.13	LUIICII

### **SESSION IV - STAGING AND ADJUVANT**

Chairman: Philip Poortmans

## 14.15 Appropriate staging work-up in early breast cancer lassem lacek

## 14.45 **Is there a role for adjuvant bisphosphonates?**Robert Coleman

15 15 Discussion

#### **SESSION V - GUIDELINES**

Chairman: Philip Poortmans

## 15.30 Role of guidelines in the era of personalized cancer medicine

- Do guidelines impact on patients outcome? Petra Boelens
- Genomics platforms as decision making tools Miguel Martin
- 16.30 Adjourn

# 17.30 Ceremony for the presentation of the University of Padua Award for Advances Breast Cancer 2014 and the Monica Boscolo Research Grant

- 18.00 Lecture of the Awardee
- 18.30 Cocktail

The Ceremony and the cocktail will take place in Palazzo Bo, Via VIII Febbraio 2, Padua.

## Friday, November 7th

### **SESSION VI - EARLY BREAST CANCER**

## 9.00 Adjuvant - Clinical Case Discussion I

Chairmen: Pier Franco Conte, Miguel Martin

Presenters of the cases: Zora Baretta, Cristina Falci

The presenter will introduce a clinical case and will ask questions to the audience. The discussants will comment the vote and will review the state of art

### Discussants:

- Fertility preservation Lucia Del Mastro
- Adjuvant therapy for low risk HER2+ patients Valentina Guarneri

- Endocrine adjuvant therapy in premenopause Stephen Johnston
- Extended adjuvant endocrine therapy Jonas Bergh
- 10.45 Discussion
- 11.00 Coffee break

## 11.30 Neoadjuvant – Clinical Case Discussion II

Chairmen: Fernando Bozza, Pier Franco Conte

Presenters of the cases: Silvia Michieletto, Tania Saibene

The presenter will introduce a clinical case and will ask questions to the audience. The discussants will comment the vote and will review the state of art

#### Discussants:

- Locoregional management Philip Poortmans
- HR+/HER2 negative Stephen Johnston
- Triple negative breast cancer Maria Vittoria Dieci
- Adjuvant therapy in suboptimal responders after neoadjuvant therapy Pier Franco Conte
- 13.15 Discussion
- 13.30 Lunch

## **SESSION VII - ADVANCED BREAST CANCER**

Chairmen: Valentina Guarneri, Sibylle Loibl

#### 14 30 Clinical case discussion III

The presenter will introduce a clinical case and will ask questions to the audience. The discussants will comment the vote and will review the state of art.

## Sequence and duration of anti-HER2 therapy

Presenter: Cristina Falci Discussant: Pier Franco Conte

## Therapeutic options for HR+ disease

Presenter: Carlo Alberto Giorgi Discussant: Gabriel N. Hortobagyi

## Triple negative advanced breast cancer

Presenter: Giovanni Faggioni Discussant: Sabine Charlotte Linn

- 16.15 Discussion
- 16.30 Coffee break

Chairmen:	Gabriel	N.	Hortobagyi	Donato	Nitt
CITATI IIICIII	CGDIICI		110160000	201100	1 41 6 61

#### 16.45 Clinical case discussion IV

The presenter will introduce a clinical case and will ask questions to the audience. The discussants will comment the vote and will review the state of art.

### BRCA test as tool for therapy selection

Presenter: Zora Baretta Discussant: Miguel Martin

## Surgery of the primary in de novo stage IV disease

Presenter: Antonella Brunello Discussant: Miranda Ernst

- 18.00 Discussion
- 18.10 Adjourn

## Saturday, November 8th

#### **SESSION VIII - HIGHLIGHTS OF THE YEAR**

Chairmen: Jonas Bergh, Stefania Gori

## 9.00 Advances in biology

Aleix Prat

## 9.30 HR+/HER2- disease

Stephen Johnston

### 10.00 HER2+ disease

Fabio Puglisi

## 10.30 Triple negative disease

Cornelia Liedtke

#### 11 00 Coffee break

#### **SESSION IX - COMING SOON**

Chairman: Gabriel N. Hortobagyi

## 11.30 New promising drugs

Jonas Bergh

## 12.00 Trials likely to impact on clinical practice in the near future: EBC

Sibylle Loibl

## 12.30 Trials likely to impact on clinical practice in the near future: ABC

Paolo Pronzato

13.00 Adjourn and final evaluation questionnaire

## **Directors**

#### Pier Franco Conte

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I)

#### Gabriel N. Hortobagyi

Department of Breast Medical Oncology University of Texas MD Anderson Cancer Center Houston (USA)

# Scientific Committee

#### Jonas Bergh

Department of Oncology-Pathology Karolinska Institute and University Hospital Stockholm (SW)

#### Valentina Guarneri

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I)

#### Jacek Jassem

Department of Oncology and Radiotherapy Medical University of Gdansk (PL)

#### Stephen Johnston

NIHR Biomedical Research Centre for Cancer Royal Marsden NHS Foundation Trust & Institute of Cancer Research London (UK)

#### Sibylle Loibl

German Breast Group Department of Medicine and Reasearch University of Frankfurt (D)

#### Miguel Martin

Medical Oncology Service Hospital Universitario Gregorio Maranon Madrid (S)

#### Donato Nitti

Department of Surgery, Oncology and Gastroenterology University of Padua (I)

#### **Philip Poortmans**

President-elect of ESTRO Department of Radiation Oncology Radboud University Medical Centre Nijmegen (NL)

# Speakers

#### Alberto Amadori

Division of Oncological Molecular Diagnostic and Immunology Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I)

#### Enrica Baldan

Breast Unit Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS University of Padua (I)

#### Nicola Balestrieri

Breast Center Cà Foncello Regional Hospital ULSS 9 Treviso (I)

#### Zora Baretta

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS University of Padua (I)

#### Jonas Bergh

Department of Oncology-Pathology Karolinska Institute and University Hospital Stockholm (SW)

#### Giampaolo Bianchini

Department of Medical Oncology IRCCS San Raffaele Hospital Milan (I)

#### Petra Boelens

Department of Surgery Leiden University Medical Center Leiden (NL)

#### Fernando Bozza

Division of Breast Surgery Istituto Oncologico Veneto IRCCS Padua (I)

#### Antonella Brunello

Division of Medical Oncology 1 Istituto Oncologico Veneto IRCCS Padua (I)

#### Robert E. Coleman

Academic Unit of Clinical Oncology Weston Park Hospital - University of Sheffield Sheffield (UK)

#### Pier Franco Conte

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I)

#### Alessandro Coran

Breast Imaging Unit Istituto Oncologico Veneto IRCCS Padua (I)

#### Lucia Del Mastro

Medical Oncology A- Innovative therapies development IRCCS A.O.U. San Martino - IST Genoa (I)

#### Maria Vittoria Dieci

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I)

#### Miranda Ernst

Division of Oncology Surgery Alexander Monro Clinic Bilthoven (NL)

#### Giovanni Faggioni

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Padua (1)

#### Cristina Falci

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS University of Padua (I)

#### Carlos A. Garcia-Etienne

Division of Breast Surgery Humanitas Research Hospital Rozzano (I)

#### Carlo Alberto Giorgi

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Padua (I)

#### Stefania Gori

Department of Medical Oncology Sacro Cuore - Don Calabria Hospital Negrar, VR (I)

#### Valentina Guarneri

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I)

#### Gabriel N. Hortobagyi

Department of Breast Medical Oncology University of Texas MD Anderson Cancer Center Houston (USA)

#### Jacek Jassem

Department of Oncology and Radiotherapy Medical University of Gdansk (PL)

#### Stephen Johnston

NIHR Biomedical Research Centre for Cancer Royal Marsden NHS Foundation Trust & Institute of Cancer Research London (UK)

#### Cornelia Liedtke

Campus Lübeck Department of Gynecology and Obstetrics University Hospital of Schleswig-Holstein Lubeck (D)

#### Sabine Charlotte Linn

Dept. of Medical Oncology The Netherlands Cancer Institute Antoni van Leeuwenhoek Amsterdam (NL)

#### Sibylle Loibl

German Breast Group Department of Medicine and Reasearch University of Frankfurt (D)

#### Graziano Meneghini

Breast Center ULSS 5 Ovest Vicentino Montecchio Maggiore (VI)

#### Miguel Martin

Medical Oncology Service Hospital Universitario Gregorio Maranon Madrid (S)

#### Silvia Michieletto

Division of Breast Surgery Istituto Oncologico Veneto IRCCS Padua (I)

#### Donato Nitti

Department of Surgery, Oncology and Gastroenterology University of Padua (I)

#### Pietro Panizza

Department of Diagnostic Radiology IRCCS National Cancer Institute Milan (I)

#### Luigi Pescarini

Department of Radiology Diagnostic Breast Unit Istituto Oncologico Veneto IRCCS University of Padua (I)

#### Ilaria Polico

Breast Imaging Unit Istituto Oncologico Veneto IRCCS Padua (1)

#### **Philip Poortmans**

President- elect of ESTRO Department of Radiation Oncology Radboud University Medical Centre Nijmegen (NL)

#### Aleix Prat

Institute of Oncology (VHIO) Vall d'Hebron Barcellona (E)

#### Paolo Pronzato

Medical Oncology IRCCS A.O.U. San Martino - IST Genoa (I)

#### Fabio Puglisi

Department of Oncology University Hospital of Udine (I)

#### Massimo Rugge

General Pathology & Cytopathology Unit Department of Medicine-DIMED University of Padua (I)

#### Tania Saibene

Division of Breast Surgery Istituto Oncologico Veneto IRCCS Padua (I)

#### Anna Sapino

Department of Biomedical Science and Human Oncology University of Torino (I)

#### Petra Steyerova

Clinic of Radiology General University Hospital Center for Breast Disease of V. Polak Prague (CZ)

## Awards

#### MONICA BOSCOLO RESEARCH GRANT

The Scientific Committee will select the winner of the Monica Boscolo Research Grant. This Research Award is restricted to young Italian researchers (< 40 years) who will carry out a research project at a foreign institution.

#### UNIVERSITY OF PADUA AWARD FOR ADVANCES IN BREAST CANCER 2014

The Scientific Committee will select young researchers (< 40 years from any country) who have published in an international peer-reviewed journal, as the principal author, a manuscript reporting important clinical or biological advances in breast cancer. Prof. Conte and Prof. Hortobagyi will select the final winner which will be invited to present his/her study during the annual Conference

## **Under 35**

Free admission is available for 5 persons "Under 35". Registration forms will be accepted on a first-come, first-served basis until spaces are filled. The Organization Secretariat will confirm the registration by email.





Based on the in force Italian regulations, Accademia Nazionale di Medicina (provider n. 31) will assign to the activity CME (31-99451): **8 CME points**.

The Meeting is addressed to physicians specialized in: oncology, radiodiagnostics, radiotherapy, clinical pathology, general surgery, gynaecology and obstetrics, biologists and nurses.

It will not be possible to give credits to physicians specialized in different fields.

The credit certification is subject to:

- attendance at the entire Meeting
- the completion of the meeting evaluation form
- the completion of the final questionnaire (at least 75% of correct answers)

We would like to remind to participants that only 1/3 of CME credits acquired during the years 2014/2016 can come frome a sponsorship.

# Official Language

The official language of the Meeting is English. No simultaneous translation will be provided.

## Registration

The registration fee is € 250,00 tax free.

It includes the conference bag, the conference book and all coffee breaks and lunches. It does not include Hotel accomodation, dinners and travel expenses.

Under the article 54 T.U.I.R and within the limits set out therein, the costs of participation in this activity are deductible in determining self-employment income.

To register, please send:

- registration form duly filled out (even when sponsored by a Pharmaceutical Company
- privacy statement and consent to the use of personal data (as in the back of the form)
- payment

to Accademia Nazionale di Medicina – Palazzina CUP II Piano, Via Massarenti 9, 40138 Bologna (fax 0039 051 6364605 – e.mail: info.bologna@accmed.org, within october 27th, 2014.

Registration guote can be paid by: non-transferable cheque addressed to Accademia Nazionale di Medicina; bank transfer addressed to: ACCADEMIA NAZIONALE DI MEDICINA, Banca Intesa Spa - Filiale 2475 –Ge-Marose - IBAN code: IT 27 J 03069 01460 615257596948 - SWIFT code: BCITITMM (indicate: "Registration of Dr. ... at Course 14 RE 1064); Credit Card Details Mastercard. Visa, Eurocard (NO AMEX).

Online registration is possible on the website <a href="http://meettheprofessor.accmed.org">http://meettheprofessor.accmed.org</a>

By submitting the form and the payment, your registration is completed with the exception of specific decisions of the Meeting Secretariat.

Incomplete registration will NOT be admitted.

The registration will be confirmed by e-mail, please put your e-mail address on the registration form.

## **CANCELLATION**

- if the participants minimum number is not reached, Accademia Nazionale di Medicina will advise by a written communication and proceed with the total refund of the fee.
- In order to cancel please give advise with a written communication to Accademia Nazionale di Medicina within 10 days from the beginning. A 70% of the registration fee will be returned. Any cancellation after that deadline will not be reimbursed.

# Meeting Venue

Centro Congressi Padova A. Luciani Via Forcellini 170/A Padova Tel. +39 049/8033711

## How to reach the meeting venue:

By Car:

The Highway exits are Padova Est, 5 Km from the Meeting Venue Padova Zona Industriale, 6 Km from the Meeting Venue

## By Train:

Padova is in the Center of Veneto, it is easy to reach with the trains Milano-Venezia and Bologna-Venezia. The Meeting Venue is 4 Km from the train station

By Plane

Venezia Airport - Marco-Polo: 43 km (about 40 minutes by car) Treviso Airport- Canova: 63 km (about 50 minutes by car)

# With the patronage of

### **INSTITUTIONS**









Dipartimento di Scienze Chirurgiche Oncologiche e Gastroenterologiche DiSCOG







## **SCIENTIFIC SOCIETIES**

















# With the unconditional contribution of

#### **GOLD SPONSOR**





### SILVER SPONSOR









### **BRONZE SPONSOR**





### **CONTRIBUTORS**

- > EISAI
- > GENOMIC HEALTH
- > MYRIAD GENETICS
- > PHARMA MAR
- > PIERRE FABRE PHARMA
- > SANOFI AVENTIS

